Patient characteristics
| Characteristic . | No. (%) . |
|---|---|
| Total patients | 150 (100) |
| Male sex | 80 (53) |
| Male donor | 96 (64) |
| Median age (IQR), y | 57 (50-65) |
| Median donor age (IQR), y | 28 (22-40) |
| Donor | |
| Related | 33 (22) |
| Unrelated | 117 (78) |
| Graft source | |
| Peripheral blood stem cell | 131 (87) |
| Bone marrow | 19 (13) |
| HLA match | |
| MRD 10/10 allele matched | 30 (20) |
| MUD 10/10 + 9/10 allele matched | 98 (65) |
| MUD 1 antigen mismatch | 19 (13) |
| Haploidentical | 3 (2) |
| Underlying disease* | |
| Acute leukemia | 58 (39) |
| Other | 92 (61) |
| Disease risk† | |
| High | 51 (34) |
| Low | 99 (66) |
| Karnofsky score at aHSCT | |
| <90 | 25 (17) |
| 90-<100 | 72 (48) |
| 100 | 51 (34) |
| NA | 2 (1) |
| Conditioning regimen | |
| Myeloablative | 62 (41) |
| Nonmyeloablative | 88 (59) |
| Radiation | |
| None | 38 (25) |
| ≤400 Gy | 88 (59) |
| ≥1200 Gy | 24 (16) |
| T-cell depletion | |
| Yes | 17 (11) |
| No | 133 (89) |
| Characteristic . | No. (%) . |
|---|---|
| Total patients | 150 (100) |
| Male sex | 80 (53) |
| Male donor | 96 (64) |
| Median age (IQR), y | 57 (50-65) |
| Median donor age (IQR), y | 28 (22-40) |
| Donor | |
| Related | 33 (22) |
| Unrelated | 117 (78) |
| Graft source | |
| Peripheral blood stem cell | 131 (87) |
| Bone marrow | 19 (13) |
| HLA match | |
| MRD 10/10 allele matched | 30 (20) |
| MUD 10/10 + 9/10 allele matched | 98 (65) |
| MUD 1 antigen mismatch | 19 (13) |
| Haploidentical | 3 (2) |
| Underlying disease* | |
| Acute leukemia | 58 (39) |
| Other | 92 (61) |
| Disease risk† | |
| High | 51 (34) |
| Low | 99 (66) |
| Karnofsky score at aHSCT | |
| <90 | 25 (17) |
| 90-<100 | 72 (48) |
| 100 | 51 (34) |
| NA | 2 (1) |
| Conditioning regimen | |
| Myeloablative | 62 (41) |
| Nonmyeloablative | 88 (59) |
| Radiation | |
| None | 38 (25) |
| ≤400 Gy | 88 (59) |
| ≥1200 Gy | 24 (16) |
| T-cell depletion | |
| Yes | 17 (11) |
| No | 133 (89) |
All data are no. (%) unless otherwise stated.
IQR, interquartile range; MRD, matched related donor; MUD, matched unrelated donor; NA, not available.
Underlying diseases include acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia, acute nonlymphocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and chronic ALL.
Factors for high risk of disease include greater than first complete remission or primary induction failure for acute leukemia, non-Hodgkin leukemia, Hodgkin l, chronic lymphocytic leukemia, myelodysplastic syndrome (MDS) with refractory anemia and excess blasts, prolymphocytic leukemia (PLL), and severe aplastic anemia. Factors for low risk of disease include first complete remission of acute leukemia; biphenotypic, bilineage, or hybrid leukemia; chronic myeloblastic leukemia; Diamond-Blackfan anemia; MDS (minus refractory anemia with excess blasts); precursor T-cell lymphoblastic lymphoma; peripheral T-cell lymphoma; splenic marginal zone B-cell lymphoma; PLL T-cell lymphoma, and PLL B-cell lymphoma.